This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech

Is the 'January Effect' Signaling a Down Year for the Stock Market?

Is the 'January Effect' Signaling a Down Year for the Stock Market?

CNBC's 'Fast Money Halftime' trading panel took a look at how stocks have shaped up for the first month of 2015 and what that means for the next 11 months.

01/30/15 - 03:14 PM EST

IPO Roundup: Shake Shack Shares More Than Double Out of Gate

Investors were eating up shares of Shake Shack as the stock more than doubled after the fast-casual burger chain's stock debuted on the New York Stock Exchange.

01/30/15 - 11:52 AM EST

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.

01/30/15 - 08:39 AM EST

IPO Roundup: Shake Shack Shares More Than Double Out of Gate

IPO Roundup: Shake Shack Shares More Than Double Out of Gate

Investors were eating up shares of Shake Shack as the stock more than doubled after the fast-casual burger chain's stock debuted on the New York Stock Exchange.

01/30/15 - 11:52 AM EST

Dendreon's Asset Rummage Sale Completes the Circle of Life

Dendreon's Asset Rummage Sale Completes the Circle of Life

Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.

01/30/15 - 06:01 AM EST

Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat

Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat

  • Tickers in this article:
  • RDY

Dr. Reddy's (RDY) shares were up today after the company reported third quarter results that beat analysts' guidance.

01/29/15 - 04:54 PM EST

Vertex Pharmaceutical (VRTX) Stock Declines Today Following Earnings Realease

Vertex Pharmaceutical (VRTX) Stock Declines Today Following Earnings Realease

  • Tickers in this article:
  • VRTX

Vertex Pharmaceutical (VRTX) shares are falling today after the company reported a wider year over year quarterly loss and analysts' tepid response to the tone of its conference call

01/29/15 - 11:44 AM EST

Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?

Can Regulus Therapeutics Double Again on Next Hep-C Drug Trial Update?

New trial data from a group of hepatitis C patients treated with a higher dose of RG-101 are expected in early February, according to Regulus

01/28/15 - 02:28 PM EST

The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M

The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M

If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.

01/29/15 - 07:44 AM EST

Amgen (AMGN) Stock Declines Today Despite Earnings Beat

Amgen (AMGN) Stock Declines Today Despite Earnings Beat

  • Tickers in this article:
  • AMGN

Amgen (AMGN) shares are falling following the release of the company's fourth quarter earnings results today.

01/28/15 - 12:30 PM EST

Abbot Laboratories (ABT) Stock Gains Today on $5.3 Billion Generic Business Sale Approval

Abbot Laboratories (ABT) Stock Gains Today on $5.3 Billion Generic Business Sale Approval

  • Tickers in this article:
  • ABT

Abbot Laboratories (ABT) shares are rising after the European Commission announced its approval of the company's generic business sale to Mylan (MYL).

01/28/15 - 01:55 PM EST

Novartis (NVS) Stock Gains Today on Earnings Beat

Novartis (NVS) Stock Gains Today on Earnings Beat

  • Tickers in this article:
  • NVS

Novartis (NVS) shares are climbing on the company's strong fourth quarter financial performance.

01/27/15 - 04:15 PM EST

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Medtronic's $49.9 billion acquisition of Covidien -- the largest tax inversion deal ever -- will leave shareholders with a big tax bill, while Medtronic may pay little or no taxes.

01/28/15 - 06:01 AM EST

Bristol-Myers Squibb (BMY) Stock Falls Today on Weak Guidance

Bristol-Myers Squibb (BMY) Stock Falls Today on Weak Guidance

  • Tickers in this article:
  • BMY

Bristol-Myers Squibb (BMY) shares are declining after it issued weak 2015 guidance today.

01/27/15 - 12:42 PM EST

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs